Resources
Peer-Reviewed Articles (open access)
- 2021 AHA/ACC Guideline for the Evaluation of Chest Pain
- 2014 AHA/ACC Guideline for the Management of Patients
With Non–ST-Elevation Acute Coronary Syndromes - Recommendations for Institutions
Transitioning to High-Sensitivity
Troponin Testing - Fourth Universal Definition of Myocardial Infarction (2018)
Videos
- Evidence Based Medicine and the Use of High Sensitivity Troponin
- High Sensitivity Troponin General Education
- High-Sensitivity Troponin in Clinical Practice: From Evidence to Implementation
Requires account and log in access via MedScape - The Value of High-Sensitivity Troponin: Optimizing Outcomes & Operations in the Emergency Department
Requires account and log in access via MedScape
Conversion to High-Sensitivity Cardiac Troponin Test
As part of an enterprise wide implementation of Roche Diagnostics clinical chemistry and immunoassay test platforms, TriCore will be converting to a high-sensitivity cardiac troponin T test to improve the management of chest pain patients with suspected acute coronary syndromes.
This conversion will not occur on the same date across all TriCore laboratories. It is expected to begin in July 2022 and conclude in late 2024. Notification of the conversion for a given laboratory will be communicated to the appropriate stakeholders in advance of the change.
This web page contains important information and educational resources regarding the conversion from a contemporary cardiac troponin test to a high sensitivity cardiac troponin test and will be updated as new details and resources become available.
Questions regarding this conversion can be directed to either:
Dr. David Grenache
Laboratory Director, Core Laboratory
505.938.8647
Dr. Melissa Budelier
Medical Director, Clinical Chemistry & Toxicology
505.938.8460